PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2021; 121(08): 1079-1086
DOI: 10.1055/a-1333-5536
Coagulation and Fibrinolysis

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Maria Elisa Mancuso 
1   Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center–IRCCS, Rozzano, Milan, Italy
,
Mark T. Reding
2   University of Minnesota Medical Center, Minneapolis, Minnesota, United States
,
Claude Negrier
3   Louis Pradel University Hospital, University Claude Bernard Lyon 1, Lyon, France
,
Bryce A. Kerlin
4   Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, United States
,
Savita Rangarajan
5   University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
,
Mindy L. Simpson
6   Rush University Medical Center, Chicago, Illinois, United States
› Institutsangaben Funding This study was funded by Bayer.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

BAY 94-9027 (damoctocog alfa pegol, Jivi) is an extended-half-life recombinant factor VIII (rFVIII) shown to be well-tolerated and efficacious in bleeding prevention in previously treated patients with severe hemophilia A. During the PROTECT VIII study, prophylaxis patients received BAY 94-9027 at intervals determined based on their bleeding phenotype, observed during a 10-week run-in treatment period with twice-weekly dosing. Those with ≤ 1 spontaneous joint or muscle bleed were randomized to either 45 to 60 IU/kg every 5 days or 60 IU/kg every 7 days; patients could increase dosing frequency to every 5 days or twice weekly in the case of bleeds. Those enrolled after the randomization arms were full, and those with ≥ 2 bleeds in the run-in period, received 30 to 40 IU/kg twice weekly. Patients completing the main study could receive open-label BAY 94-9027 in the extension phase. Dosing regimen, total, and joint annualized bleeding rates were analyzed over three periods: prestudy, main study, and extension. A total of 80 patients who were on prophylaxis treatment prior to and during the study and had prior bleed data available were evaluated in this post hoc analysis of PROTECT VIII. Most patients (> 80%) required fewer infusions with BAY 94-9027 prophylaxis versus their previous standard-half-life (SHL) rFVIII product. Lower bleeding and joint bleeding rates were observed over time from the prestudy to the extension study period in all treatment regimens. Compared with SHL FVIII, BAY 94-9027 prophylaxis allows patients to reduce infusion frequency with maintained or improved protection from bleeds.

Keywords

annualized bleeding rate - hemophilia A - prophylaxis - recombinant factor VIII - target joint


Publikationsverlauf

Eingereicht: 07. Mai 2020

Angenommen: 08. Dezember 2020

Accepted Manuscript online:
09. Dezember 2020

Artikel online veröffentlicht:
28. Februar 2021

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedGoogle Scholar
  • 2 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (04) 700-710
    CrossrefPubMedGoogle Scholar
  • 3 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
    CrossrefPubMedGoogle Scholar
  • 4 Aledort LM, Haschmeyer RH, Pettersson H. The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (04) 391-399
    CrossrefPubMedGoogle Scholar
  • 5 Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015; 13 (Suppl. 01) S176-S179
    CrossrefPubMedGoogle Scholar
  • 6 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10) 989-998
    CrossrefPubMedGoogle Scholar
  • 7 Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy -- global progress towards optimal care. Haemophilia 2006; 12 (01) 75-81
    CrossrefPubMedGoogle Scholar
  • 8 Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol 2015; 8 (02) 237-246
    CrossrefPubMedGoogle Scholar
  • 9 Collins PW, Blanchette VS, Fischer K. et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (03) 413-420
    CrossrefPubMedGoogle Scholar
  • 10 Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol 2019; 36 (03) 141-154
    PubMedGoogle Scholar
  • 11 Mei B, Pan C, Jiang H. et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116 (02) 270-279
    CrossrefPubMedGoogle Scholar
  • 12 Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12 (04) 488-496
    CrossrefPubMedGoogle Scholar
  • 13 Reding MT, Ng HJ, Poulsen LH. et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost 2017; 15 (03) 411-419
    CrossrefPubMedGoogle Scholar
  • 14 Thomson G. et al. Effective protection for >5 years with BAY 94-9027 prophylaxis: interim results from the PROTECT VIII extension trial. Poster Presentations. Haemophilia 2018; 24: 32-135
    CrossrefPubMedGoogle Scholar
  • 15 Reding MT, Ng HJ, Tseneklidou-Stoefer D, Linardi C, Laelzari S. Safety of long-term prophylaxis with BAY 94-9027: interim results of >5 years of treatment in the PROTECT VIII extension trial. Haemophilia 2018; 24 (S5): x
    PubMedGoogle Scholar
  • 16 European Medicines Agency. JIVI Summary of Product Characteristics. 2018 . Accessed January 2019 at: https://www.ema.europa.eu/documents/product-information/jivi-epar-product-information_en.pdf
    PubMedGoogle Scholar
  • 17 Pharmaceuticals and Medical Devices Agency. 2018 . Accessed January 2021 at: https://www.pmda.go.jp/files/000229786.pdf
    PubMed
  • 18 US Food and Drug Administration. JIVI Antihemophilic Factor (Recombinant) PEGylated-aucl Prescribing Information. 2018 . Accessed January 2019 at: https://www.fda.gov/downloads/BiologicsBloodVaccines/UCM618979.pdf
    PubMedGoogle Scholar
  • 19 Batt K, Gao W, Ayyagari R. et al. Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A. J Blood Med 2019; 10: 147-159
    CrossrefPubMedGoogle Scholar
  • 20 Lalezari S, Reding MT, Pabinger I. et al. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia 2019; 25 (06) 1011-1019
    CrossrefPubMedGoogle Scholar
  • 21 Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8 (09) 1895-1902
    CrossrefPubMedGoogle Scholar
  • 22 Mulder K, Llinás A. The target joint. Haemophilia 2004; 10 (Suppl. 04) 152-156
    CrossrefPubMedGoogle Scholar
  • 23 Aznar JA, García-Dasí M, Pérez-Alenda S. et al. Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre. Vox Sang 2014; 106 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 24 Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12 (Suppl. 03) 117-121
    CrossrefPubMedGoogle Scholar
  • 25 Reding MT, Pabinger I, Lalezari S, Santagostino E, Mancuso ME. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. Haemophilia 2020; 26 (04) e201-e204
    CrossrefPubMedGoogle Scholar
  • 26 Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia 2018; 24 (03) 414-419
    CrossrefPubMedGoogle Scholar
  • 27 von Mackensen S, Kalnins W, Krucker J. et al. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia 2017; 23 (04) 566-574
    CrossrefPubMedGoogle Scholar
  • 28 Shah A, Coyle T, Lalezari S. et al. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies. Haemophilia 2018; 24 (05) 733-740
    CrossrefPubMedGoogle Scholar
  • 29 Valentino LA, Pipe SW, Collins PW. et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016; 22 (04) 514-520
    CrossrefPubMedGoogle Scholar